Korro Bio Inc (KRRO)

$14.16 +1.52 (11.98%)
Market Cap 163.27M
Revenue (ttm) 6.39M
Net Income (ttm) -117.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,835.05%
Debt to Equity Ratio 0.00
Volume 156,612
Avg Vol 258,118
Day's Range N/A - N/A
Shares Out 14.42M
Stochastic %K 98%
Beta 2.98
Analysts Strong Sell
Price Target $18.67

Company Profile

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The c...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 468 1999
Address:
One Kendall Square, Building 600-700 Suite 6-401, Cambridge, United States
prismmarketview
prismmarketview Apr. 2 at 4:32 PM
PRISM Mid-Day Movers: Pharmaceuticals and Global Health are Today’s Leaders. Biodexa Pharmaceuticals (Nasdaq: $BDRX) is surging to about $1.05, up roughly 70% on heavy volume, yet still down over 90% in the past year as it heads into an April 6, 2026 1‑for‑5 ADR reverse split and remains a speculative, catalyst‑driven oncology play in tough‑to‑treat cancers. Lexaria Bioscience (Nasdaq: $LEXX) is trading just under $1.00, up about 17% as investors eye upcoming GLP‑1 catalysts following positive Human Pilot Study #5 data showing its oral DehydraTECH‑liraglutide performed comparably to injected Saxenda and kicking off a 2026 R&D program with new human and multi‑arm animal GLP‑1 studies. Other Notable Movers: BioStem Technologies ( $BSEM) up 16% Korro Bio ( $KRRO) up 10% Lipocine Inc ( $LPCN) down -78% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-global-health-are-todays-leaders/
0 · Reply
PhishTourFunds
PhishTourFunds Apr. 2 at 1:38 AM
$KRRO M&A 🎯
0 · Reply
Ilygod
Ilygod Mar. 31 at 2:06 PM
$KRRO Next biotech to be bought out.
0 · Reply
Estimize
Estimize Mar. 24 at 10:03 PM
Wall St is expecting -2.07 EPS for $KRRO Q4 [Reporting 03/31 AMC] http://www.estimize.com/intro/krro?chart=historical&metric_name=eps&utm_c
0 · Reply
InTheMoney_
InTheMoney_ Mar. 20 at 10:27 PM
$KRRO $SPY $QQQ insider cluster buying 🔥🔥 https://finshort.com/KRRO/insiders
0 · Reply
lowside
lowside Mar. 20 at 2:00 AM
$KRRO But here’s the part people miss This specific situation is not a “pure signal” 1. It was part of a financing deal Many shares + warrants were bought directly from the company That means: They’re funding the company, not just betting on stock going up 👉 This is different from insiders buying on the open market with their own cash only.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 18 at 11:30 AM
$KRRO Q4 '25 Earnings Results & Recap Korro Bio anticipates a regulatory filing for KRRO-121 in H2 2026 to commence a first-in-human trial and expects to nominate an AATD development candidate in Q2 2026, with cash runway into H2 2028.
0 · Reply
mikesterz7
mikesterz7 Mar. 16 at 1:32 AM
$KRRO Mohamad Makhzoumi, a ten percent owner of Korro Bio, Inc. has purchased 207,100 shares of common stock at a price of $11.11, for a total value of $2,300,881
0 · Reply
NoMoneyPlayer
NoMoneyPlayer Mar. 16 at 1:09 AM
$KRRO Shit will be lit!!!
0 · Reply
InTheMoney_
InTheMoney_ Mar. 16 at 1:07 AM
$KRRO $SPY HUGE cluster buying. 9 Insiders 🔥🔥🔥🔥 https://finshort.com/KRRO/insiders
0 · Reply
Latest News on KRRO
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook

Mar 13, 2026, 1:02 PM EDT - 20 days ago

Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 4:05 PM EDT - 20 days ago

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Korro Announces Oversubscribed $85 Million Private Placement

Mar 9, 2026, 7:30 AM EDT - 24 days ago

Korro Announces Oversubscribed $85 Million Private Placement

Korro to Present at the TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 5 weeks ago

Korro to Present at the TD Cowen 46th Annual Health Care Conference

Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript

Jan 29, 2026, 3:42 PM EST - 2 months ago

Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript

Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 20, 2026, 11:46 AM EST - 2 months ago

Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Korro to Host Virtual Analyst Day on January 27, 2026

Jan 20, 2026, 8:00 AM EST - 2 months ago

Korro to Host Virtual Analyst Day on January 27, 2026

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 8:00 AM EST - 3 months ago

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Korro Bio Early Trial Results Fall Short; Stock Hits New Low

Nov 13, 2025, 2:26 PM EST - 4 months ago

Korro Bio Early Trial Results Fall Short; Stock Hits New Low

This biotech is halting its work with Novo Nordisk and laying off more people

Nov 12, 2025, 5:59 PM EST - 5 months ago

This biotech is halting its work with Novo Nordisk and laying off more people

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

Nov 12, 2025, 4:05 PM EST - 5 months ago

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

Korro to Participate in Upcoming Investor and Scientific Conferences

Sep 2, 2025, 4:30 PM EDT - 7 months ago

Korro to Participate in Upcoming Investor and Scientific Conferences

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 7:00 AM EDT - 8 months ago

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

Jul 21, 2025, 8:00 AM EDT - 9 months ago

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

Korro to Participate in Upcoming Investor Conferences

May 14, 2025, 4:05 PM EDT - 11 months ago

Korro to Participate in Upcoming Investor Conferences

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025, 4:30 PM EDT - 11 months ago

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Mar 14, 2025, 8:00 AM EDT - 1 year ago

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Korro to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

Korro to Present at the TD Cowen 45th Annual Health Care Conference

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Nov 21, 2024, 7:30 AM EST - 1 year ago

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Korro to Present at the Jefferies London Healthcare Conference

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Nov 4, 2024, 7:25 AM EST - 1 year ago

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Korro to Participate in Upcoming September Investor and Scientific Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Korro to Participate in Upcoming September Investor and Scientific Conferences

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

Korro to Participate in Upcoming June Investor and Scientific Conferences

May 30, 2024, 4:01 PM EDT - 1 year ago

Korro to Participate in Upcoming June Investor and Scientific Conferences

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

May 20, 2024, 2:30 PM EDT - 2 years ago

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

May 14, 2024, 4:01 PM EDT - 2 years ago

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

Korro Announces $70 Million Private Placement

Apr 18, 2024, 8:30 AM EDT - 2 years ago

Korro Announces $70 Million Private Placement

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Mar 26, 2024, 4:01 PM EDT - 2 years ago

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

Mar 14, 2024, 5:34 PM EDT - 2 years ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRYS MREO TAK WVE

Korro to Present at the TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 2 years ago

Korro to Present at the TD Cowen 44th Annual Health Care Conference

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Jan 18, 2024, 8:00 AM EST - 2 years ago

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Dec 7, 2023, 8:00 AM EST - 2 years ago

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Nov 28, 2023, 8:00 AM EST - 2 years ago

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Nov 3, 2023, 3:31 PM EDT - 2 years ago

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Nov 3, 2023, 12:19 PM EDT - 2 years ago

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ

Oct 6, 2023, 2:14 PM EDT - 2 years ago

FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

Korro Bio and Frequency Therapeutics Announce Merger Agreement

Jul 14, 2023, 6:30 AM EDT - 2 years ago

Korro Bio and Frequency Therapeutics Announce Merger Agreement

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

May 12, 2023, 4:01 PM EDT - 3 years ago

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Mar 10, 2023, 7:30 AM EST - 3 years ago

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Feb 27, 2023, 7:30 AM EST - 3 years ago

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth

Feb 23, 2023, 7:45 AM EST - 3 years ago

Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Feb 13, 2023, 8:05 AM EST - 3 years ago

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

Dec 19, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

Dec 15, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

prismmarketview
prismmarketview Apr. 2 at 4:32 PM
PRISM Mid-Day Movers: Pharmaceuticals and Global Health are Today’s Leaders. Biodexa Pharmaceuticals (Nasdaq: $BDRX) is surging to about $1.05, up roughly 70% on heavy volume, yet still down over 90% in the past year as it heads into an April 6, 2026 1‑for‑5 ADR reverse split and remains a speculative, catalyst‑driven oncology play in tough‑to‑treat cancers. Lexaria Bioscience (Nasdaq: $LEXX) is trading just under $1.00, up about 17% as investors eye upcoming GLP‑1 catalysts following positive Human Pilot Study #5 data showing its oral DehydraTECH‑liraglutide performed comparably to injected Saxenda and kicking off a 2026 R&D program with new human and multi‑arm animal GLP‑1 studies. Other Notable Movers: BioStem Technologies ( $BSEM) up 16% Korro Bio ( $KRRO) up 10% Lipocine Inc ( $LPCN) down -78% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-global-health-are-todays-leaders/
0 · Reply
PhishTourFunds
PhishTourFunds Apr. 2 at 1:38 AM
$KRRO M&A 🎯
0 · Reply
Ilygod
Ilygod Mar. 31 at 2:06 PM
$KRRO Next biotech to be bought out.
0 · Reply
Estimize
Estimize Mar. 24 at 10:03 PM
Wall St is expecting -2.07 EPS for $KRRO Q4 [Reporting 03/31 AMC] http://www.estimize.com/intro/krro?chart=historical&metric_name=eps&utm_c
0 · Reply
InTheMoney_
InTheMoney_ Mar. 20 at 10:27 PM
$KRRO $SPY $QQQ insider cluster buying 🔥🔥 https://finshort.com/KRRO/insiders
0 · Reply
lowside
lowside Mar. 20 at 2:00 AM
$KRRO But here’s the part people miss This specific situation is not a “pure signal” 1. It was part of a financing deal Many shares + warrants were bought directly from the company That means: They’re funding the company, not just betting on stock going up 👉 This is different from insiders buying on the open market with their own cash only.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 18 at 11:30 AM
$KRRO Q4 '25 Earnings Results & Recap Korro Bio anticipates a regulatory filing for KRRO-121 in H2 2026 to commence a first-in-human trial and expects to nominate an AATD development candidate in Q2 2026, with cash runway into H2 2028.
0 · Reply
mikesterz7
mikesterz7 Mar. 16 at 1:32 AM
$KRRO Mohamad Makhzoumi, a ten percent owner of Korro Bio, Inc. has purchased 207,100 shares of common stock at a price of $11.11, for a total value of $2,300,881
0 · Reply
NoMoneyPlayer
NoMoneyPlayer Mar. 16 at 1:09 AM
$KRRO Shit will be lit!!!
0 · Reply
InTheMoney_
InTheMoney_ Mar. 16 at 1:07 AM
$KRRO $SPY HUGE cluster buying. 9 Insiders 🔥🔥🔥🔥 https://finshort.com/KRRO/insiders
0 · Reply
stocklio_dot_ai
stocklio_dot_ai Mar. 15 at 9:38 PM
$KRRO Volume Spike — 4.7x average volume
0 · Reply
Br331
Br331 Mar. 15 at 9:09 PM
$KRRO scam
1 · Reply
GuruChartist
GuruChartist Mar. 15 at 9:05 PM
$KRRO
0 · Reply
History101
History101 Mar. 15 at 8:38 PM
$KRRO 2,816 watching 3/15/2026
0 · Reply
History101
History101 Mar. 15 at 8:35 PM
$KRRO well, i should have bought some shares on the selloff, if not then then at least in late December. With recent $85MM oversubscribed private placement, I'm thinking about slowly adding again over time. GLTALs!!
0 · Reply
Almostmadeit
Almostmadeit Mar. 15 at 8:34 PM
$KRRO big up for KRRO
0 · Reply
lowside
lowside Mar. 13 at 9:38 PM
$KRRO If im seeing correctly then 35m insider buys reported yesterday!
0 · Reply
unbreakable01
unbreakable01 Mar. 13 at 7:54 PM
$KRRO 💩 market, however I’m holding this one.
0 · Reply
erevnon
erevnon Mar. 13 at 3:17 PM
Cantor Fitzgerald maintains Korro Bio $KRRO at Overweight and raises the price target from $21 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 1:49 PM
Top Gainers PT2 $DEVS $KRRO $CXAI $LOCO $MEHA
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 13 at 1:33 PM
$KRRO ramping
0 · Reply